Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial - New Study
Anti-PD-1 therapy in unresectable desmoplastic melanoma: the phase 2 SWOG S1512 trial Summary The SWOG S1512 phase 2 trial investigated pembrolizumab (anti-PD-1 therapy) in patients with unresectable desmoplastic melanoma (DM), a rare and aggressive subtype. The study found pembrolizumab demonstrated a promising objective response rate (ORR) in DM patients. Importantly, the trial showed that a…


















